dupilumab · Dupixent
Monoclonal antibody
Also known as REGN668
Evidence outlook
Approved: Asthma, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease, Chronic Spontaneous Urticaria, Prurigo Nodularis, Eosinophilic Esophagitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (7)
- Allergic Fungal Rhinosinusitis: DUPIXENT for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery
- Treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery
- Chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid
- Dupixent as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils
- Treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments
- Atopic Dermatitis DUPIXENT (dupilumab injection) is indicated for the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. Asthma DUPIXENT is indicated as an add-on maintenance treatment in patients aged 6 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma. DUPIXENT is not indicated for relief of acute bronchospasm...
- Atopic dermatitis Adults and adolescents Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Children 6 months to 11 years of age Dupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. Asthma Adults and adolescents Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01949311 NCT01949311 · Atopic Dermatitis This was an explicitly described open-label extension enrolling participants from prior dupilumab atopic dermatitis trials, including the SOLO 1 and SOLO 2 programs, with 2,677 participants receiving dupilumab in a single group. The primary outcomes were safety events rather than a comparative efficacy endpoint, and there was no randomization, blinding, or control arm; therefore, the findings provide limited evidence despite the large enrollment. Its registered primary outcome on ClinicalTrials.gov is "Number of Treatment Emergent Adverse Events (TEAEs)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT01949311 | 3 | Number of Treatment Emergent Adverse Events (TEAEs) (Up to 272 weeks); OPTIONAL SUB-STUDY: Number of Adverse Events of Special Interest (AESIs) Through the Last Study Visit After Switching to the New Dupilumab Drug Product (Up to 24 Weeks) 2022-06-27 | Number of Treatment Emergent Adverse Events (TEAEs) (Up to 272 weeks): Dupilumab 14717 Number of Events | Weak signal | link ↗ |
View 8 more trials
SOLO 1 NCT02277743 · Atopic Dermatitis The trial was randomized, triple-blind, placebo-controlled, and included 671 participants, with the clinical primary endpoint significantly favoring both dupilumab regimens: 37.9% and 37.2% achieved the specified IGA response versus 10.3% with placebo (both p<0.0001). The registry does not report a primary-endpoint power calculation, so the study is presented as moderate rather than strong evidence despite its otherwise rigorous design. Registry: NCT02277743 | 3 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 2015-11 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 (Week 16): Dupilumab 300 mg q2w 37.9% | Dupilumab 300 mg qw 37.2% vs Placebo 10.3% | Partial signal | link ↗ |
SOLO 2 NCT02277769 · Atopic Dermatitis The trial was randomized, triple-blind, placebo-controlled, and included 708 participants, with an objective clinical skin-severity primary endpoint. The primary endpoint was met for both dupilumab regimens, but the record does not report a power calculation needed to verify that the study was adequately powered, so the evidence is graded moderate rather than strong. Registry: NCT02277769 | 3 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 2015-10-31 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 (Week 16): Dupilumab 300 mg q2w 36.1% | Dupilumab 300 mg qw 36.4% vs Placebo 8.5% | Partial signal | link ↗ |
CHRONOS NCT02260986 · Atopic Dermatitis This was a randomized, triple-blind, placebo-controlled trial of 740 participants, and its clinical primary endpoint was met for both dupilumab regimens: IGA response was 38.7% with 300 mg every 2 weeks and 39.2% weekly versus 12.4% with placebo, with p<0.0001 for each comparison. The registry does not report a primary-endpoint power calculation, so the evidence is graded moderate despite the strong blinded design and statistically significant result. Registry: NCT02260986 | 3 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 (Baseline to Week 16) 2015-08 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 (Baseline to Week 16): Dupilumab 300 mg q2w 38.7% | Dupilumab 300 mg qw 39.2% vs Placebo qw 12.4% | Partial signal | link ↗ |
SOLO-CONTINUE NCT02395133 · Atopic Dermatitis This was a randomized, triple-blind, placebo-controlled trial of 422 prior responders, and both clinical primary endpoints (loss of eczema improvement and keeping a 75% eczema score improvement at week 36) were met for every dupilumab regimen against placebo. Registry: NCT02395133 | 3 | Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769) (Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study)); Percentage of Participants With Eczema Area and Severity Index >= 75% [EASI-75] at Baseline of Current Study Maintaining EASI-75 at Week 36 2016-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT03054428 NCT03054428 · Atopic Dermatitis This was a randomized, quadruple-blind, placebo-controlled phase 3 trial in 251 adolescents, and both clinical co-primary endpoints (clear or almost clear skin and 75% improvement in eczema severity at week 16) were met for both dupilumab regimens. A power calculation called for 80 patients per group, and every group enrolled at least 82. Registry: NCT03054428 | 3 | Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction From Baseline of ≥2 Points) at Week 16 (Baseline and Week 16); Percentage of Participants With Eczema Area and Severity Index (EASI)-75 (≥75% Improvement From Baseline) at Week 16 (Baseline and Week 16) 2018-04-04 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT03345914 NCT03345914 · Atopic Dermatitis This was a randomized, quadruple-blind, placebo-controlled phase 3 trial in 367 children, and its clinical primary endpoint (clear or almost clear skin at week 16) was met for both dupilumab regimens (p=0.0004 and p<0.0001). A power calculation set a target of about 330 patients, and 367 were enrolled. Registry: NCT03345914 | 3 | Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 2019-06-20 | Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4% | Reliable signal | link ↗ |
Liberty AD NCT03346434 · Atopic Dermatitis This grade covers the randomized part of the trial: 162 young children were assigned at random and double-blind to dupilumab or placebo, and both clinical primary endpoints (clear or almost clear skin and 75% improvement in eczema severity at week 16) were met with p<0.0001. A power calculation set a target of 160 children for this part, and 162 were randomized. Registry: NCT03346434 | 2/3 | Part A: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Dose Normalized Maximum Observed Serum Concentration (Cmax/Dose) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Time to Reach the Maximum Serum Concentration (Tmax) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Last Quantifiable Serum Concentration (Clast) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Time of the Last Quantifiable Serum Concentration (Tlast) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Dose Normalized Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast/Dose) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) (Baseline up to Week 4); Part A: Number of Participants With TEAEs by Severity According to Qualitative Toxicity Scale (Baseline up to Week 4); Part B: Percentage of Participants With Investigator's Global Assessment (IGA) Score 0 or 1 at Week 16; Part B: Percentage of Participants With Eczema Area and Severity Index (EASI) -75 (EASI-75) (≥75% Improvement From Baseline) at Week 16 2021-07-08 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT04417894 NCT04417894 · Moderate to Severe Atopic Hand and Foot Dermatitis This was a randomized, quadruple-blind, placebo-controlled trial in 133 patients, and its clinical primary endpoint (clear or almost clear hands and feet at week 16) was met, 40.3% vs 16.7% (p=0.0030). A power calculation set a target of 130 patients, and 133 were enrolled. Registry: NCT04417894 | 3 | Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 2022-08-31 | Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7% | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (46)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (51)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (57)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (22)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Studied as part of a combination product (1)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 4 (1)
What this study did
Appears in other studies (2)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 1 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other IL-4R-alpha drugs
GS101, Manfidokimab, QL2108, Rademikibart, SHR-1819 and 5 more. Compare all 11 IL-4R-alpha drugs
This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Chronic Obstructive Pulmonary Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dupilumab (Dupixent): this drug | Approved | Monoclonal antibody | IL-4R-alpha | Partial signal | NCT04456673: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.295 Exacerbation per participant-year (95% CI 1.048 to 1.6) | Dupilumab 300 mg q2w 0.859 Exacerbation per participant-year (95% CI 0.699 to 1.057) NCT03930732: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.01 exacerbation per participant-year (95% CI 0.931 to 1.301) | Dupilumab 300 mg q2w 0.776 exacerbation per participant-year (95% CI 0.645 to 0.934) | |
| Aclidinium Bromide (Tudorza Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Partial signal | NCT03022097: Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. NCT00891462: Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1) (Change from Baseline to 12 weeks): Aclidinium Bromide, 200µg 0.062 L (Standard Error 0.015) | Aclidinium Bromide, 400µg 0.099 L (Standard Error 0.015) vs Placebo -0.025 L (Standard Error 0.015) | |
| Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair) | ApprovedUS marketing discontinued | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | Partial signal | NCT03022097: Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) NCT02796677: Week 24, AB/FF 400/12 ug: 1-hour post-dose FEV1 vs aclidinium 400 ug +0.084 L (95% CI 0.051 to 0.117), p<0.0001; trough FEV1 vs formoterol 12 ug +0.055 L (95% CI 0.023 to 0.088), p=0.0009. Monotherapy primary: aclidinium vs tiotropium trough FEV1 +0.007 L (95% CI -0.021 to 0.035), non-inferior at the -50 mL margin (CT.gov posted results). | |
| Budesonide / Formoterol Fumarate (SYMBICORT) | Approved | Combination | Glucocorticoid receptor; Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | Reliable signal | NCT02465567: Rate of moderate/severe COPD exacerbations: PT010 (the trial's investigational triple therapy) reduced the rate by 24% vs glycopyrronium/formoterol fumarate (PT003) (p<0.001), and by 13% vs budesonide/formoterol fumarate (PT009) (p=0.003) NCT02497001: Primary 1, FEV1 AUC0-4 at week 24, BGF MDI vs BFF MDI: LS mean difference 116 mL (95% CI 80 to 152; p<0.0001), met. Primary 2, change from baseline in morning pre-dose trough FEV1 at week 24, BGF MDI vs GFF MDI: 13 mL (95% CI -9 to 36; p=0.2375), missed. Separate Europe/Canada analysis over 24 weeks: FEV1 AUC0-4 vs BFF MDI +104 mL (95% CI 77 to 131; p<0.0001) and vs BUD/FORM DPI +91 mL (p<0.0001); trough FEV1 vs GFF MDI +22 mL (95% CI 4 to 39; p=0.0139), all met. | |
| Ensifentrine (Ohtuvayre) | Approved | Small molecule | PDE3/PDE4 | Reliable signal | NCT05743075: Placebo-corrected change from baseline in FEV1 AUC0-12h at Week 12: +110 mL for ensifentrine (p<0.0001) NCT04535986: Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12 (Baseline (pre-dose on Day 1) and Week 12): Ensifentrine 0.0611 liters (Standard Error 0.01825) vs Placebo -0.0256 liters (Standard Error 0.0195) | |
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal | NCT02164513: Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) NCT02345161: Co-primary 1, trough FEV1 change to week 24 (ITT): +142 mL with FF/UMEC/VI vs -29 mL with budesonide/formoterol (LS mean difference 171 mL, 95% CI 148 to 194; P<0.001), met. Co-primary 2, SGRQ total score change to week 24 (ITT): -6.6 vs -4.3 units (LS mean difference -2.2, 95% CI -3.5 to -1.0; P<0.001), met. Supportive week-52 analyses in the extension subset: FEV1 difference 179 mL (95% CI 131 to 226; P<0.001); SGRQ difference -2.7 (95% CI -5.5 to 0.2; P=0.065), not significant. | |
| Fluticasone Furoate / Vilanterol (Breo Ellipta) | Approved | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | Partial signal | NCT01313676: Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants missed | |
| Fluticasone Propionate / Salmeterol (Advair Diskus) | Approved | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | Weak signal | Featured results are non-efficacy only in this race | |
| Ipratropium | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | not yet graded | No reviewed efficacy summary in this indication | |
| Ipratropium / Albuterol | Approved | Small molecule | Muscarinic M3 receptor / Beta-2 adrenergic receptor (combination) | not yet graded | No reviewed efficacy summary in this indication | |
| Mepolizumab (Nucala) | Approved | Monoclonal antibody | IL-5, Interleukin-5 (IL-5), ligand-neutralizing | Partial signal | NCT04133909: Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Mepolizumab 100 mg 0.8 Exacerbations per year (95% CI 0.7 to 0.91) | Placebo 1.01 Exacerbations per year (95% CI 0.89 to 1.15) | |
| Olodaterol | Approved | Small molecule | Beta-2 adrenergic receptor | Reliable signal | NCT00782210: FEV1 AUC0-3h response at Day 85 (Week 12), difference from placebo: olodaterol 5 mcg +0.172 L (SE 0.019), P<0.0001; olodaterol 10 mcg +0.176 L (SE 0.019), P<0.0001 (study 1222.11, n=624). NCT00796653: Week 24, olodaterol 5 and 10 ug vs placebo: FEV1 AUC0-3h +0.129 and +0.154 L (both p<0.0001); trough FEV1 +0.053 L (p=0.0055) and +0.069 L (p=0.0003); TDI focal score in this study +0.402 (p=0.1999) and +0.419 (p=0.1818), not significant; TDI in the combined analysis +0.509 (p=0.0270) and +0.525 (p=0.0203) (CT.gov posted results). | |
| Olodaterol / Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Revefenacin (Yupelri) | Approved | Small molecule | Muscarinic receptors (antagonist) | Reliable signal | NCT05046795: Trough FEV1 on Day 85 (Baseline and Day 85): Revefenacin Inhalation Solution 175 mcg QD. 55.12 mL (Standard Error 23.974) vs Placebo Inhalation Solution QD. -95.78 mL (Standard Error 24.504) NCT02459080: Study 0126: trough FEV1 change at day 85 vs placebo +79 mL with revefenacin 88 µg (p=0.0003) and +146 mL with revefenacin 175 µg (p<0.0001). | |
| Roflumilast (Daliresp) | Approved | Small molecule | PDE4 | not yet graded | No reviewed efficacy summary in this indication | |
| Salmeterol (DISKUS) | Approved | Small molecule | Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Partial signal | NCT02172287: Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. | |
| Umeclidinium (Incruse Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Reliable signal | NCT02184611: Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) NCT01387230: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Baseline and Day 85): Placebo -0.007 Liters (Standard Error 0.028) | UMEC 62.5 µg 0.12 Liters (Standard Error 0.0257) | UMEC 125 µg 0.145 Liters (Standard Error 0.0268) | |
| Umeclidinium / Vilanterol | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | Reliable signal | NCT01777334: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) NCT01716520: Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by Response Type (Baseline and Day 14 of each treatment period (up to study day 83)): UMEC/VI 62.5/25 µg — Responder to UMEC, n=90, 90, 88: 0.337 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.331 Liters (Standard Error 0.0148); Responder to Neither, n=36, 37, 36: 0.13 Liters (Standard Error 0.0243) vs UMEC 62.5 µg — Responder to UMEC, n=90, 90, 88: 0.216 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.189 Liters (Standard Error 0.015); Responder to Neither, n=36, 37, 36: 0.077 Liters (Standard Error 0.0243) | VI 25 µg — Responder to UMEC, n=90, 90, 88: 0.201 Liters (Standard Error 0.0167); Responder to VI, n=99, 102, 100: 0.233 Liters (Standard Error 0.0147); Responder to Neither, n=36, 37, 36: 0.057 Liters (Standard Error 0.024) | |
| Astegolimab | Phase 3 | Monoclonal antibody | ST2 (IL1RL1) | Partial signal | NCT05595642: ARNASA (NCT05595642), primary endpoint annualized COPD exacerbation rate (AER) at 52 weeks: astegolimab showed a numerical 14.5% reduction vs placebo, not statistically significant missed NCT05037929: Annualized COPD exacerbation rate reduced by a statistically significant 15.4% vs placebo at 52 weeks with every-two-weeks dosing | |
| Beclomethasone Dipropionate / Formoterol Fumarate | Phase 3 | Small molecule | Glucocorticoid receptor; β2-adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow) | Phase 3 | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal | No reviewed efficacy summary in this indication | |
| Depemokimab | Phase 3 | Monoclonal antibody | IL-5 | not yet graded | No reviewed efficacy summary in this indication | |
| Felcorekibart | Phase 3 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| HSK39004 | Phase 3 | Small molecule | Phosphodiesterase 3 and Phosphodiesterase 4 (PDE3/PDE4) | not yet graded | No reviewed efficacy summary in this indication | |
| Lunsekimig | Phase 3 | Antibody-derived scaffold | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| REGEND001 | Phase 3 | Cell therapy | Airway epithelial regeneration (autologous basal cells) | Partial signal | No reviewed efficacy summary in this indication | |
| Tezepelumab (Tezspire) | Phase 3 | Monoclonal antibody | TSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizing | not yet graded | No reviewed efficacy summary in this indication | |
| Tilrekimig | Phase 3 | Multispecific antibody | IL-4/IL-13/TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Tozorakimab | Phase 3 | Monoclonal antibody | IL-33 | Partial signal | NCT06040086: Primary endpoint met: statistically significant reduction in the annualised rate of moderate-to-severe COPD exacerbations in former smokers and the overall population (MIRANDA, AstraZeneca, 2026-04-20). NCT05158387: Primary endpoint met: tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations vs placebo in former smokers and the overall population (TITANIA, 2026-03-27). | |
| TQC3721 | Phase 3 | Small molecule | PDE3/PDE4 | Partial signal | NCT06527144: Primary endpoint, change in peak FEV1 at week 4 vs placebo: 3 mg +100 mL (95% CI 41 to 159; P = .0011); 6 mg +147 mL (95% CI 93 to 201; P < .0001) (PACER-II, CHEST 2026). | |
| Stapokibart | Phase 2/3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| 9MW1911 | Phase 2 | Monoclonal antibody | IL-33/ST2, ST2 (IL1RL1) | Weak signal | Featured results are safety only in this race | |
| Alvelestat | Phase 2 | Small molecule | Neutrophil elastase | Partial signal | NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively). | |
| AZD6793 | Phase 2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| Dexpramipexole | Phase 2 | Small molecule | Eosinophil maturation/survival (mitochondrial) | not yet graded | No reviewed efficacy summary in this indication | |
| Glasmacinal | Phase 2 | Small molecule | Airway epithelial barrier integrity | Partial signal | NCT05516316: Primary endpoint (BALF IL-8 after inhaled LPS challenge, 375 mg EP395 daily for 3 weeks vs placebo) not met. BALF IL-6, TNF-alpha, MIP-1alpha, MIP-1beta and MCP-1 were lower and IL-33, IL-8, IL-1beta, neutrophil elastase and myeloperoxidase higher with EP395 (none statistically significant). Serum SP-D rose with EP395 (mean 148.8 to 183.0 ng/mL at 24 h, p=0.0007) but not with placebo. missed | |
| HRS-9821 | Phase 2 | Small molecule | PDE3/PDE4 | Weak signal | No reviewed efficacy summary in this indication | |
| Ocankitug | Phase 2 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| PBF-680 | Phase 2 | — | Adenosine A1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pegtarazimod | Phase 2 | Peptide | Complement C1q / neutrophil effectors (myeloperoxidase, NETosis) | not yet graded | No reviewed efficacy summary in this indication | |
| Rademikibart | Phase 2 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| RC1416 | Phase 2 | Multispecific antibody | IL-4 / IL-5 / IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| RSS0343 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Solizmestrocel | Phase 2 | Cell therapy | Regenerative/anti-inflammatory (MSC) | Weak signal | No reviewed efficacy summary in this indication | |
| Verekitug | Phase 2 | Monoclonal antibody | TSLP receptor | not yet graded | No reviewed efficacy summary in this indication | |
| WIN378 | Phase 2 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| XKH001 | Phase 2 | Monoclonal antibody | IL-25 | not yet graded | No reviewed efficacy summary in this indication | |
| KIT2014 | Phase 1/2 | Peptide | PDE3/PDE4 | not yet graded | No reviewed efficacy summary in this indication | |
| APG808 | Phase 1(overall) | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| BBT002 | Phase 1 | Multispecific antibody | IL-4Ralpha / IL-5 | not yet graded | No reviewed efficacy summary in this indication | |
| Frevecitinib | Phase 1 | Small molecule | JAK1/2/3/TYK2 | Weak signal | No reviewed efficacy summary in this indication | |
| GDC-6988 | Phase 1 | Small molecule | TMEM16A (Anoctamin-1) calcium-activated chloride channel | not yet graded | No reviewed efficacy summary in this indication | |
| GSK3862995 | Phase 1 | Monoclonal antibody | IL-33 | not yet graded | No reviewed efficacy summary in this indication | |
| PUR1800 | Phase 1 | Small molecule | Narrow-spectrum kinase (p38/Syk-family) | not yet graded | No reviewed efficacy summary in this indication | |
| REGEND007 | Phase 1 | Cell therapy | Airway basal layer stem cells | not yet graded | No reviewed efficacy summary in this indication | |
| Ensifentrine / Glycopyrrolate | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK6759821 | —(overall) | RNA / oligonucleotide | — | not yet graded | No reviewed efficacy summary in this indication | |
| RG6527 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Itepekimab | Discontinued | Monoclonal antibody | IL-33 | Partial signal | NCT04701983: Annualized rate of moderate/severe AECOPD, reduction vs placebo at Week 52: 27% (every-2-week dosing arm), statistically significant primary endpoint met NCT04751487: AERIFY-2 (NCT04751487), annualized rate of moderate/severe AECOPD exacerbations vs placebo at Week 52 (the primary-endpoint timepoint): 2% reduction with itepekimab every-2-weeks, 12% reduction with itepekimab every-4-weeks; neither reached statistical significance missed |
Large race: only the 63 furthest-along competitors are listed; 1 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(35 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Dupixent (dupilumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (4)
November 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (18)
January 2027 (2)
February 2027 (1)
What to watch
March 2027 (2)
April 2027 (2)
June 2027 (3)
July 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (5)
2028 (9)
February 2028 (2)
May 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (1)
What to watch
December 2028 (4)
What to watch
What to watch
What to watch
What to watch
2029 (2)
2031 (1)
June 2031 (1)
What to watch
2034 (1)
September 2034 (1)
What to watch
Regulatory and conference events
(9)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent